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InﬂammationIn recent years, chronic immune activation and systemic inﬂammation have emerged as hallmarks of HIV disease
progression and mortality. Several studies indicate that soluble inﬂammatory biomarkers (sCD14, IL-6, IL-8, CRP
and hyaluronic acid), as well as surface markers of T-cell activation (CD38, HLA-DR) independently predict pro-
gression to AIDS andmortality in HIV-infected individuals.While co-infections have been shown to contribute to
immune activation, the impact of latent tuberculosis infection (LTBI), which is widely endemic in the areas most
affected by the global AIDS epidemic, has not been evaluated.We hypothesized that both active and latent states
of Mycobacterium tuberculosis co-infection contribute to elevated immune activation as measured by these
markers. In HIV-infected individuals with active, but not latent TB, we found elevated levels of soluble markers
associated with monocyte activation. Interestingly, T-cell activation was elevated individuals with both latent
and active TB. These results suggest that in the highly TB- and HIV-endemic settings of southern Africa, latent
TB-associated T-cell activation may contribute to HIV disease progression and exacerbate the HIV epidemic.
In addition, our ﬁndings indicate that aggressive campaigns to treat LTBI in HIV-infected individuals in high-
burden countries will not only impact TB rates, but may also slow HIV progression.
Signiﬁcance: Latent tuberculosis, which affects an estimated 1/3 of theworld's population, has long been thought
to be a relatively benign, quiescent state ofM. tuberculosis infection. While HIV co-infection is known to exacer-
bateM. tuberculosis infection and increase the risk of developing active TB, little is known about the potential ef-
fect of latent TB infection on HIV disease. This study shows that HIV-infected individuals with both active and
latent TB have elevated levels of inﬂammation and immune activation, biomarkers of HIV disease progression
and elevated risk of mortality. These results suggest that, in the context of HIV, latent TB infection may be asso-
ciated with increased risk of progression to AIDS and mortality.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ved by the relevant IRBs and all
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Although the incidence of HIV has peaked in much of sub-
Saharan Africa, the tuberculosis (TB) epidemic continues unabated
with TB remaining the leading cause of death in those living with
HIV (World Health Organization, 2014). While many studies have
investigated the impact of HIV infection on anti-TB immunity, the inter-
action betweenMycobacterium tuberculosis (M. tb) infection and HIV dis-
ease progression is less well understood. Previous work suggests that in
the absence of combination antiretroviral therapy (cART), the progression
of HIV infection to AIDS andmortality among HIV-infected people in sub-
Saharan Africamay be higher than inWestern populations (Morgan et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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co-infections in these settings may play a role.
Recent studies have demonstrated that elevated levels of certain
soluble markers of inﬂammation or hyperactivation of the innate
immune system can independently predict progression to AIDS, im-
mune reconstitution inﬂammatory syndrome (IRIS), and death in HIV-
infected patients (Boulware et al., 2011; Sandler et al., 2011; Marchetti
et al., 2013). Speciﬁcally, solublemarkers ofmonocyte turnover, inﬂam-
mation, and ﬁbrosis, including soluble CD14 (sCD14), lipopolysaccharide,
interleukin (IL)-6, IL-8, interferon gamma-induced protein 10 (IP-10),
hyaluronic acid, and C-reactive protein (CRP) have been shown to be as-
sociated with increased risk of progression to AIDS and death (Boulware
et al., 2011; Hasegawa et al., 2009; Neuhaus et al., 2010; French et al.,
2009).
Markers of lymphocyte activation have also been shown to predict
disease progression in HIV-infected patients. Immune activation,
as measured by the elevated expression of CD38 or co-expression
of CD38 and HLA-DR on T-cells has been shown to be associated with
shorter survival, transient low level viremia, drop in CD4+ T-cell
count, and mortality upon initiation of cART (Giorgi et al., 1993, 1999;
Hunt et al., 2003, 2011a; Deeks et al., 2004; Sousa et al., 2002;
Vujkovic-Cvijin et al., 2013; Zhang et al., 2013; Taiwo et al., 2013; Dillon
et al., 2014). Certain co-infections such as cytomegalovirus (CMV), hep-
atitis C virus (HCV), and hepatitis B virus (HBV) have been shown to
contribute to immune activation in HIV-infected individuals (Hunt
et al., 2011b; Beltran et al., 2014; Crane et al., 2014; Marchetti et al.,
2014).
The impact of M. tb co-infection on immune activation during HIV
infection has not been fully characterized. Active TB has been shown
to contribute to immune activation and inﬂammation in the absence
of HIV infection (Bloom et al., 2012, 2013). Additionally, active TB has
been implicated in elevated plasma sCD14 and increased T-cell activa-
tion in HIV co-infected individuals (Toossi et al., 2013; Lawn et al.,
2000; Mahan et al., 2010). However, the impact of latent TB infection,
which affects an estimated 1/3 of people worldwide and an estimated
77–88% of adults in South Africa (Barry et al., 2009; Hanifa et al., 2009;
Wood et al., 2010), on either soluble markers of inﬂammation or lym-
phocyte activation in HIV-patients has not been assessed.
We hypothesized that markers of deleterious inﬂammation and
immune activation would be elevated in individuals with both latent
and active TB infection. We sought to determine whether HIV-infected
persons in KwaZulu-Natal, South Africa showed increased levels of solu-
ble and cellular inﬂammatory biomarkers based on their TB infection sta-
tus. To this end, we measured the plasma levels of sCD14, CRP, IL-6, IL-8,
IP-10, and hyaluronic acid, and the lymphocyte expression of CD38 and
HLA-DR in HIV-infected individuals with no evidence of TB infection,
latent TB infection (LTBI), and active TB disease.
2. Materials and Methods
2.1. Patient Selection
80 HIV-positive individuals with well-deﬁned states of TB infection
were included in this study. All patients were participants in the
iThimba (n = 64), Sinikithemba (n = 12), or the “Diagnosis of smear
negative HIV associated pulmonary tuberculosis using a novel
intra-esophageal device” (TB String Study, n = 4) cohorts based in
KwaZulu-Natal, South Africa. Ethical approval was obtained andwritten
informed consent was obtained from all patients. All subjects were
HIV-positive and were categorized into one of three states of TB
co-infection: (1) active TB infection, (2) latent TB infection, or (3) no ev-
idence of TB infection. All subjects were ART, TB therapy, and isoniazid
prophylaxis therapy (IPT) — naïve at the time of assessment. BCG
vaccination history was not documented, but all subjects were likely
vaccinated in infancy per South African standards. Subjects with active TB
(AT) were deﬁned as having symptoms of pulmonary TB and a culture-positive sputum (spontaneous or induced) for M. tb. Subjects from the
iThimba cohortwith latent TB (LTBI)were deﬁned as having no TB symp-
toms, having a tuberculin skin test (TST) with induration greater than
5 mm, a positive ESAT-6 and/or CFP-10 (RD-1) speciﬁc IFN-γ ELISpot,
an induced sputum that was culture-negative forM. tb, and normal lung
parenchyma on chest-X ray (CXR). Subjects from the iThimba cohort
with no evidence of TB infection (no TB) were deﬁned as having no TB
symptoms, a negative TST, a negative RD-1 ELISpot, an induced sputum
that was culture-negative forM. tb and normal lung parenchyma on CXR.
Because there were differences in the availability between cryopre-
served plasma and peripheral blood mononuclear cells (PBMCs), two
distinct but overlapping groupings of subjects were utilized in this
study. The number of subjects in each group and their characteristics
are detailed in Tables 1 and 2. Sample sizes for each comparison were
calculated to provide 80% power to detect effect sizes drawn from pre-
vious studies at a Bonferroni-corrected level of signiﬁcance ranging
from 0.025–0.008.
2.2. Soluble Biomarker Analysis
Cryopreserved plasma from a subset of subjects fromwhom plasma
was available was assayed for concentration of the following bio-
markers using a multiplexed bead-based immunoassay: IL-6, IL-8, and
IP-10 (all Invitrogen; Carlsbad, CA). sCD14 (R&D Systems; Minneapolis,
MN) andCRP (Invitrogen)were alsomeasured by bead-based immuno-
assays. All plasma was thawed once, aliquoted, and thawed once more
for use in this analysis. Assays were performed according to the
manufacturer's instructions and analyzed on a BioPlex-200 Luminex
system (Bio-Rad; Hercules, CA). Plasma concentrations of hyaluronic
acid were assayed by ELISA (Corgenix; Broomﬁeld, CO) according to the
manufacturer's instructions.
2.3. Flow Cytometric Analysis
Cryopreserved peripheral blood mononuclear cells (PBMCs) from a
subset of subjects from whom PBMCs were available were thawed
and rested overnight at 37 °C in order to minimize the effect of cellular
activation due to thawing. All antibodies were pre-titrated in order to
determine appropriate working concentrations. Rested PBMCs
were then stained with the following antibodies: aqua viability
dye (Invitrogen), CD3-PECF594 (BD; Franklin Lakes, NJ; clone
UCHT1), CD4-PerCP-Cy5.5 (Biolegend; San Diego, CA; clone RPA-
T4), CD8-APC-H7 (BD, clone SK1), CD38-PECy7 (BD, clone HIT2),
and HLA-DR-eFluor605 (eBioscience; San Diego, CA; clone LN3).
All stains were performed at 4 °C, and cells were ﬁxed with 4% para-
formaldehyde after staining. Stained PBMCswere subsequently analyzed
on an LSR Fortessa cytometer (BD), using Rainbow Fluorescent Particles
(BD) and application settings in BDFACSDiva7 to correct for day-to-day
variations in instrument performance. Data were analyzed in FlowJo10
(Treestar; Ashland, OR). Cells were gated on aqua viability dye negative
(live), lymphocytes determined by forward scatter vs. side scatter, and
subsequently gated onCD3+CD4+orCD3+CD8+cells. Levels of activa-
tion markers (CD38 and HLA-DR) were measured by percentage positiv-
ity on CD4+ and CD8+ cells based on gates created using ﬂuorescence
minus one (FMO) controls.
2.4. Statistical Analysis
All statistical analyses were performed using GraphPad Prism 6 (La
Jolla, CA). P-values reported are for MannWhitney U or Kruskal–Wallis
tests, in the case of non-parametric data, or Student's t-test or one-way
analysis of variance (ANOVA) for parametric data. All correlations re-
portedwere tested by Spearman's rank. p values b 0.05were considered
signiﬁcant and in cases of multiple comparisons the Bonferroni correc-
tion was applied.
Table 1
Clinical and demographic characteristics of subjects compared in the analysis of soluble inﬂammatory markers.
Characteristic HIV + No TB
n = 13
HIV + LTBI
n = 21
HIV + AT
n = 28
p-Value
Age, median years (IQR) 35 (31–47) 35 (29–50) 30 (26–37) 0.09
Female sex, no. (%) 11 (85) 17 (81) 17 (63) 0.14
CD4 T-cell count, median cells/μL (IQR) 425 (322–498) 426 (358–542) 167 (30–392) b0.01
HIV RNA, median log10 copies/mL (IQR) 3.7 (3.1–4.1) 4.1 (3.2–4.7) 4.8 (3.8–5.3) 0.03
Comorbidities, no. (%) 2 (15.38) 4 (19.05) 3 (10.71) 0.72
Includes HIV-infected individuals with no evidence ofM. tb infection (no TB), HIV-infected individuals with latent TB infection (LTBI), and HIV-infected individuals with active TB (AT).
Comorbidities included arthritis (n= 2), asthma (n= 3), hypertension (n= 5), connective tissue disease (n= 1), liver disease (n= 1), and lung disease (n= 1). All subjects described
here were members of the iThimba cohort. p-Values reported for Kruskal–Wallis one-way analysis of variance.
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3.1. Plasma sCD14, CRP, IL-6, and IP-10 are Elevated in HIV-infected
Subjects With Active TB Infection
Our ﬁrst aimwas to assess the effect of latent and active TB infection
on soluble inﬂammatory biomarkers that have been shown to predict
poor outcomes in HIV-infected individuals. Wemeasured plasma levels
of sCD14, CRP, IL-6, IL-8, IP-10, and hyaluronic acid in HIV-infected sub-
jects with no evidence of TB infection (no TB), latent TB infection (LTBI),
and active TB disease (AT, Table 1). We found no signiﬁcant differences
between levels of these plasma biomarkers for individuals with no TB
versus those with LTBI (Fig. 1). Individuals with active TB had higher
levels of sCD14 (p = 0.0076), CRP (p = 0.022), IL-6 (p = 0.0040) and
IP-10 (p=0.0185, not signiﬁcant after Bonferroni correction). Similarly,
individuals with active TB had higher levels of sCD14 (p= 0.0012), CRP
(p b 0.0001), IP-10 (p= 0.003), IL-6 (p b 0.0001) and IL-8 (p= 0.0130,
not signiﬁcant after Bonferroni correction) than those with no evidence
of TB. Levels of hyaluronic acid did not vary signiﬁcantly between the
three groups.
We foundmost of themarkers of interest to be signiﬁcantly correlat-
ed with CD4 cell count (Supplementary Fig. 1). The patients with no
evidence of TB and those with LTBI were well matched for CD4 cell
count. However, because CD4 cell count was signiﬁcantly lower in the
active TB group compared to the other two groups, we were concerned
that differences in CD4 count confounded the relationship between sol-
uble inﬂammatorymarkers and active TB. To address this, we used sam-
ples from an additional cohort (Sinikithemba) to create CD4-matchedTable 2
Clinical and demographic characteristics of subjects compared in the analysis of lymphocyte ac
Characteristic HIV + no TB
n = 13
Age, median years (IQR) 35 (31–47)
Female sex, no. (%) 11 (85)
CD4 T-cell count, median cells/μL (IQR) 425 (322–498)
HIV RNA, median log10 copies/mL (IQR) 3.7 (3.1–4.1)
Comorbidities, no. (%) 2 (15.38)
Includes HIV-infected individuals with no evidence of M. tb infection (no TB), HIV-infected indi
Comorbidities included arthritis (n= 2), hypertension (n=5), asthma (n= 2), connective tiss
the iThimba or TB String Study cohorts. p-Values reported for Kruskal–Wallis one-way analysigroups and repeated our analysis (Supplementary Table 1). Again, we
found elevated levels of sCD14 (p = 0.004), CRP (p = 0.0187), IL-6
(p = 0.0012), and IP-10 (p = 0.0366, not signiﬁcant after Bonferroni
correction), in individuals with active TB as compared to those without
active TB (Supplementary Fig. 2). Importantly, the addition of subjects
from the Sinikithemba cohort limited our ability to determine
which of the healthy, asymptomatic patients had LTBI by our strin-
gent deﬁnition, so in this analysis active TB patients were compared
to HIV-positive patients with no evidence of active TB.
Together, these data indicate that solublemarkers of immune activa-
tion are elevated in HIV-positive individuals with active TB compared to
those with either latent TB or no evidence of TB infection. We found no
difference in soluble markers of immune activation between HIV-
positive patients with no evidence of TB infection and those with latent
TB infection.
3.2. Lymphocyte Activation is Elevated in HIV-infected Individuals With
Latent and Active TB Infection
After ﬁnding elevated levels of plasma biomarkers in individuals
with active, but not latent TB, we next assessed the level of lymphocyte
activation in our groups of interest. To this end, we measured levels of
CD38 and HLA-DR on CD4+ and CD8+ T-cells in HIV-infected subjects
with no evidence of TB infection (no TB), latent TB infection (LTBI), and
active TB disease (AT, Fig. 2A). Due to availability of samples, the three
groups used for this analysis were overlapping but distinct from those
used for the plasma analysis. Deﬁnitions of TB co-infection status were
consistent. In this instance there were no statistical differences in CD4
count or viral load between the three groups (Table 2).
As expected, subjects with active TB had higher levels of T-cell acti-
vation than those with latent TB or no TB (Fig. 2). CD38 expression on
CD4+ and CD8+ T-cells was higher in those with active TB compared
to those with no TB and those with LTBI (p = (Fig. 2B and C).
Co-expression of CD38 and HLA-DR on CD4+ and CD8+ T-cells was
also higher in those with active TB compared to those with no TB and
those with LTBI (Fig. 2D and E). Interestingly, subjects with latent TB
had elevated CD38 expression on both CD4+ and CD8+ T-cells com-
pared to subjects with no evidence of TB (Fig. 2B and C). These results
were consistent when CD38 expression was evaluated by median ﬂuo-
rescence intensity (MFI) (data not shown).tivation markers.
HIV + LTBI
n = 21
HIV + AT n = 8 p-Value
35 (29–50) 33 (27–49) 0.95
17 (81) 4 (50) 0.16
426 (358–542) 286 (254–492) 0.33
4.1 (3.2–4.7) 4.4 (3.5–5) 0.4
4 (19.05) 1 (12.5) 0.91
viduals with latent TB (LTBI) and HIV-infected individuals with active pulmonary TB (AT).
ue disease (n=1), and liver disease (n= 1). All subjects described hereweremembers of
s of variance.
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Fig. 1. Plasma concentrations of A) solubleCD14 (sCD14), B) C-reactiveprotein (CRP), C) IL-6, D) IL-8, E) interferon gamma-induced protein 10 (IP-10), andF) hyaluronic acid inHIV-infected
individualswithno evidence ofM. tb infection (no TB), latent TB (LTBI), and active TB (AT). Subjects represented hereweremembers of the iThimba cohort. p-Values reported forMannWhitney
U test, with a threshold for signiﬁcance of 0.0083 after Bonferroni correction. p-Values greater than 0.0083 not displayed. Data displayed as median with interquartile range.
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We have shown that in HIV-infected individuals, both active and
latent TB co-infections are associated with biomarkers of immune acti-
vation that are known to correlatewithmore rapid HIV disease progres-
sion and mortality (Giorgi et al., 1993, 1999; Hunt et al., 2003, 2011a;
Deeks et al., 2004; Sousa et al., 2002; Vujkovic-Cvijin et al., 2013;
Zhang et al., 2013; Taiwo et al., 2013; Dillon et al., 2014). Soluble
markers of inﬂammation were elevated only in those with active TB.
In contrast, T-cell activation, as measured by CD38 and HLA-DR expres-
sion on CD4+ and CD8+ T-lymphocytes, was elevated in both latent
and active TB. Though other studies have shown that active TB con-
tributes to systemic inﬂammation in HIV-infected and uninfected indi-
viduals, the ﬁnding that individuals latently co-infected with TB alsodisplay elevated T-cell activation has not been previously described,
and may be important for understanding the interplay between HIV
and TB in individuals and in populations.
These results are particularly relevant in the context of South Africa
and other TB-endemic settings, as widespread latent TB infection and
the resultant elevated T-cell activation we have observed may provide
an explanation for more rapid progression of HIV to AIDS and increased
mortality in this setting. Additionally, repeated episodes of active TB are
often seen among HIV-infected individuals in this setting (Wood et al.,
2011), and the observed increase in inﬂammatory cytokines during
these episodes may also drive an accelerated course of HIV disease.
Our ﬁnding of increased T-cell activation may also provide addition-
al support for the treatment of latent TB infection with isoniazid in
HIV-infected individuals. While recent guidelines have recommended
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Fig. 2. A) representative ﬂow cytometry plots of CD38 and HLA-DR expression on CD8+ (top panel) and CD4+ (bottom panel) T-cells fromHIV-infected individuals with no evidence of
M. tb infection (no TB), latent TB (LTBI), or active TB (AT). Percentage of CD8+ (B) and CD4+ (D) T-cells expressing CD38 in no TB, LTBI, or AT individuals. Percentage of CD8+ (C) and
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of the iThimba or TB String Study cohorts. p-Values reported for MannWhitney U test, with p-values greater than 0.05 not displayed. Data displayed as median with interquartile range.
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on gamma release assay (IGRA)) among those co-infectedwithHIV, actu-
al coverage rates remain low (Young et al., 2009; Lawn et al., 2010). Our
work suggests that by driving immune activation, latent TB may contrib-
ute to progression to AIDS and mortality, thereby potentially adding to
the reasons for more widespread use of isoniazid preventative therapy(IPT) for those co-infectedwith LTBI andHIV. The ability of IPT to decrease
T-cell activation associated with LTBI should be tested.
A strength of this study is our use of stringent criteria for deﬁning
each patient group. To exclude the possibility of active TB in asymptom-
atic individuals, we rigorously investigated subjects in the no TB group
and LTBI group by chest X-ray and induced sputum. Though we cannot
339Z.A. Sullivan et al. / EBioMedicine 2 (2015) 334–340fully exclude the possibility of subclinical infection or undetected
extrapulmonary TB, we have used all tools available to rule out these
possibilities.We also cannot exclude the possibility that other undetect-
ed comorbidities or co-infections may have been present in our study
subjects. However, we have no evidence to suggest that these would
have been biased towards any particular study group. This study is
based on a relatively small sample size, and this factor may have limited
the extent of our ﬁndings.While our sample sizewas powered to detect
a modest to large effects in most markers, small changes would not be
identiﬁed. For example, we were unable to detect differences in plasma
concentrations of soluble biomarkers in individuals with latent TB com-
pared to thosewith no TB. While this may be due to a lack of difference,
it is also possible that with a larger sample size these two populations
might show inﬂammatory proﬁle differences. Our study population
was limited to South African subjects, which limits its extrapolation to
other populationswith less extensiveHIV epidemics and TB endemicity.
This highlights the need for further studies of HIV-associated immune
activation in settings with varying burdens of co-infection. A compara-
tive analysis of immune activation in HIV/TB co-infected individuals
fromWestern and non-Western settings would be an important com-
plement to our ﬁndings.
Our ﬁndings may reﬂect differences in the character of systemic in-
ﬂammation experienced byHIV-infected individuals livingwith varying
degrees of TB co-infection. Latently infected individuals in this study
showed lymphocyte activation but an absence of the soluble markers
of monocyte-associated activation, while those with active TB showed
signiﬁcantly elevated markers of bothmonocyte-associated and lympho-
cyte activation. These data may suggest that in HIV-infected individuals,
TB latency reﬂects a bacterial burden sufﬁcient to activate lymphocytes,
but not to cause signiﬁcant changes in plasma biomarkers of monocyte
activation. Futurework to characterize the functional capacity and activa-
tion state of TB-speciﬁc lymphocytes andmonocytes/macrophages in the
context ofHIV and LTBIwill help to clarify the interactionbetween control
of bacterial burden and immune activation.
The different mechanisms by which immune activation may be
affected by latent and active states of TB infection remain unclear, but
recent work suggests that replicating and nonreplicating bacteria may
elicit different immune responses. Mariotti et al. report that while repli-
catingM. tuberculosis is able to induce IL-1b, modulate the macrophage
inﬂammasome, and activate T-cells, nonreplicating bacteria are able to
trigger T-cell activation, but not any other inﬂammatory processes
(Mariotti et al., 2013). This observation may partially explain why la-
tently infected individuals display lymphocyte markers of activation,
while individuals with active TB disease harboring large numbers of
replicating mycobacteria have measurable inﬂammation and activation
in both the innate and adaptive branches. Further in vitro and transla-
tional work is required to test this hypothesis, aswell as to better deﬁne
themetabolic activity of bacteria in HIV-infected individuals with latent
TB co-infection.
Because previous studies of the effect of latent or active TB on immune
activation have primarily characterized HIV-uninfected individuals, and
because we were speciﬁcally interested in immune activation markers
implicated in HIV pathogenesis, we only assessed these markers in HIV
co-infected subjects. While previous studies have found no evidence for
elevated immune activation (of either bulk T-cells or M. tb-speciﬁc
T-cells) in latently-infected, HIV-negative individuals (Rodrigues et al.,
2002; Wergeland et al., 2011; de Almeida et al., 2012; Adekambi et al.,
2012; Hodapp et al., 2012), our data suggest that this is not the case for
HIV-infected individualswho also harbor latent TB infection. This surpris-
ing ﬁnding challenges the notion of latency as a fully dormant state of TB
infection, and suggests that HIV co-infection may skew this heteroge-
neous state towards a state that immunologically resembles more active
infection. Despite the rigorous deﬁnitions used to characterize individuals
as latently infected, it appears that, like active TB, latent TB may be a
fundamentally different immunological phenomenon in the context of
HIV co-infection. In a 2009 review, Barry et al. propose a redeﬁnition ofthe different stages ofM. tb infection, with ﬁve different categories of dis-
ease rather than the canonical latent vs. active dichotomy (Barry et al.,
2009). Taken into the context of this spectrum, the HIV + LTBI group
that we describe in this study while clearly not having “clinical disease”
may fall between the categories of “quiescent” and “active” infection
(Barry et al., 2009). Importantly, evidence shows that integration of isoni-
azid preventive therapy (IPT) with ART is crucial for successful treatment
of latent TB in HIV-infected individuals, further suggesting that HIV co-
infectionmay fundamentally alter latent TB and its susceptibility to treat-
ment (Houben et al., 2014). The development of improved diagnostic
tools and imaging techniques, such as positron emission tomography-
computed tomography (PET-CT) for determining an individual's place-
ment along the spectrum of TB diseasewill allow for amore nuanced pic-
ture of TB disease, and will also facilitate a deeper understanding of the
role played byHIV at different stages of TB infection (Ghesani et al., 2014).
Our results provide evidence that latent TB co-infection may be driv-
ing elevated levels of immune activation inHIV-infected individuals living
in parts of the world where TB is endemic. The differing contributions of
latent and active TB infection to activation and inﬂammation are indica-
tive of the complexity of the relationshipbetweenHIV andTB in these set-
tings and the need for larger scale and more mechanistic investigations
into these questions.
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